MedTrace Logo

Drug Use Investigation On Zithromac (Azithromycin) In HIV Patients

NCT01227395 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 476

Last updated 2013-04-26

Study results available
· View outcomes & findings →

Summary

The investigation will be conducted for the purpose of determining the condition of occurrence of Adverse Events under the actual post-marketing use of Zithromac 600mg Tablet, verifying the therapeutic effects, detecting unknown Adverse Drug Reactions and drug interactions and determining the factors affecting safety and efficacy.

Conditions

  • HIV Infection

Interventions

DRUG

Azithromycin

Inhibition of onset: Perorally administer 1200mg of azithromycin (potency) once a week to adults. Treatment: Perorally administer 600mg of azithromycin (potency) once a day to adults.

Sponsors & Collaborators

  • Altmarc Inc.

    collaborator INDUSTRY

  • Pfizer

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-07-31
Primary Completion
2012-03-31
Completion
2012-03-31

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01227395 on ClinicalTrials.gov